Featured Research

from universities, journals, and other organizations

Long-Term Stenting of Aortic Coarctation Yields 77% Success Rate

Date:
September 14, 2010
Source:
Wiley - Blackwell
Summary:
Intermediate and long-term results of stent implantation for aortic coarctation show a cumulative intermediate success of 86%, and cumulative long-term success of 77%.

Researchers from the Congenital Cardiovascular Interventional Study Consortium (CCISC) who evaluated the intermediate and long-term results of stent implantation for aortic coarctation found that cumulative intermediate success was 86%, and cumulative long-term success was 77%. Results of this study appear in the October issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

Coarctation, or narrowing, of the aorta, restricts blood flow to the lower extremities and causes hypertension and possibly heart failure. Coarctation accounts for 5-10% of all cases of congenital heart disease and has a high associated morbidity and mortality if left untreated. Treatment options for aortic coarctation include surgical approaches, transcatheter balloon angioplasty, or stent placement. Intermediate and long-term follow-up after aortic stent implantation is poorly documented, with little prospective data available on the incidence of recurrent obstruction, aortic wall complications, or blood pressure recording.

In this study, the authors report on the procedural success of stent implantation for aortic coarctation, including recurrent obstruction/repeat interventions and aortic wall complications, with a particular focus on intermediate and long-term outcomes. "This study is the largest series reported to date on stent implantation for aortic coarctation," says the lead author Ralf Holzer, MD, MSc, FSCAI. "It is the only prospective series that includes intermediate as well as long-term follow-up with integrated imaging provided by catheterization, CT, or MRI."

The study evaluated 302 patients from 34 centers from the CCISC, a prospective interventional registry that captures all types of treatment for coarctation. Patients underwent stent placement for aortic coarctation over a 9-year period between December 2000 and November 2009. Collected data included procedural, demographic, morphological, imaging and clinical data.

Clinical data was collected at baseline, before discharge, and at follow-up and included upper and lower extremity systolic/diastolic blood pressure, as well as the need for antihypertensive medication. Valid follow-up data included integrated imaging data provided by CT and/or MRI and/ or cardiac catheterization. All baseline and follow-up imaging data was evaluated for the presence of aortic wall injury (dissection and aneurysm), stent-related pathology (intimal proliferation and stent fracture), and recurrent/residual obstruction.

Forty-four percent of patients completed intermediate follow-up (3-18 months) with integrated imaging, and 21% completed long-term follow-up (>18-60 months). Acute procedural success was 96%. Acute, intermediate, and long-term procedural success was unrelated to patient weight, presence of transverse arch hypoplasia, use of compliance testing, stent type, and balloon type. Unplanned repeat interventions were required in 4% of patients, and aortic wall complications were seen in 1% of patients. Other adverse events occurred mainly acutely and included technical complications such as stent malposition. At long-term follow-up, 23% of patients continued to have systolic blood pressure above the 95th percentile, 9% had an upper-to-lower limb blood pressure gradient in excess of 20 mm Hg, and 32% were taking antihypertensive medication.

Dr. Holzer concludes, "With a long-term procedural success of 77%, an incidence of aortic wall complications of 1.3%, and a need for unplanned reintervention of 4%, the results of stent implantation compare well with other surgical and interventional series. However, even with successful initial stent therapy, patients continue to require long-term follow-up."


Story Source:

The above story is based on materials provided by Wiley - Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley - Blackwell. "Long-Term Stenting of Aortic Coarctation Yields 77% Success Rate." ScienceDaily. ScienceDaily, 14 September 2010. <www.sciencedaily.com/releases/2010/09/100914100410.htm>.
Wiley - Blackwell. (2010, September 14). Long-Term Stenting of Aortic Coarctation Yields 77% Success Rate. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/09/100914100410.htm
Wiley - Blackwell. "Long-Term Stenting of Aortic Coarctation Yields 77% Success Rate." ScienceDaily. www.sciencedaily.com/releases/2010/09/100914100410.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins